Search Results - "Veitonmäki, Niina"

Bispecific antibodies in cancer immunotherapy by Dahlén, Eva, Veitonmäki, Niina, Norlén, Per

“…Following the clinical success of immune checkpoint antibodies targeting CTLA-4, PD-1 or PD-L1 in cancer treatment, bispecific antibodies are now emerging as a…”
Get full text

Adiponectin-Induced Antiangiogenesis and Antitumor Activity Involve Caspase-Mediated Endothelial Cell Apoptosis by Bråkenhielm, Ebba, Veitonmäki, Niina, Cao, Renhai, Kihara, Shinji, Matsuzawa, Yuji, Zhivotovsky, Boris, Funahashi, Tohru, Cao, Yihai, Kishimoto, Tadamitsu

“…Obesity is a risk factor for the development of many severe human diseases such as cardiovascular disorders, diabetes, and cancer, which are tightly linked to…”
Get full text

The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation by Kvarnhammar, Anne Månsson, Veitonmäki, Niina, Hägerbrand, Karin, Dahlman, Anna, Smith, Karin Enell, Fritzell, Sara, von Schantz, Laura, Thagesson, Mia, Werchau, Doreen, Smedenfors, Kristine, Johansson, Maria, Rosén, Anna, Åberg, Ida, Winnerstam, Magnus, Nyblom, Eva, Barchan, Karin, Furebring, Christina, Norlén, Per, Ellmark, Peter

“…The CTLA-4 blocking antibody ipilimumab has demonstrated substantial and durable effects in patients with melanoma. While CTLA-4 therapy, both as monotherapy…”
Get full text

A Human ICAM-1 Antibody Isolated by a Function-First Approach Has Potent Macrophage-Dependent Antimyeloma Activity In Vivo by Veitonmäki, Niina, Hansson, Markus, Zhan, Fenghuang, Sundberg, Annika, Löfstedt, Tobias, Ljungars, Anne, Li, Zhan-Chun, Martinsson-Niskanen, Titti, Zeng, Ming, Yang, Ye, Danielsson, Lena, Kovacek, Mathilda, Lundqvist, Andrea, Mårtensson, Linda, Teige, Ingrid, Tricot, Guido, Frendéus, Björn

“…We isolated a tumor B-cell-targeting antibody, BI-505, from a highly diversified human phage-antibody library, using a pioneering “function-first” approach…”
Get full text

Angiomotin Regulates Endothelial Cell-Cell Junctions and Cell Motility by Bratt, Anders, Birot, Olivier, Sinha, Indranil, Veitonmäki, Niina, Aase, Karin, Ernkvist, Mira, Holmgren, Lars

“…We have previously identified angiomotin by its ability to bind to and mediate the anti-angiogenic properties of angiostatin. In vivo and in vitro data…”
Get full text

A DNA Vaccine Targeting Angiomotin Inhibits Angiogenesis and Suppresses Tumor Growth by Holmgren, Lars, Ambrosino, Elena, Birot, Olivier, Tullus, Carl, Veitonmäki, Niina, Levchenko, Tetyana, Carlson, Lena-Maria, Musiani, Piero, Iezzi, Manuela, Curcio, Claudia, Forni, Guido, Cavallo, Federica, Kiessling, Rolf

“…Endogenous angiogenesis inhibitors have shown promise in preclinical trials, but clinical use has been hindered by low half-life in circulation and high…”
Get full text

p130‐Angiomotin associates to actin and controls endothelial cell shape by Ernkvist, Mira, Aase, Karin, Ukomadu, Chinwe, Wohlschlegel, James, Blackman, Ryan, Veitonmäki, Niina, Bratt, Anders, Dutta, Anindya, Holmgren, Lars

“…Angiomotin, an 80 kDa protein expressed in endothelial cells, promotes cell migration and invasion, and stabilizes tube formation in vitro. Angiomotin belongs…”
Get full text

Suppression of Angiogenesis and Tumor Growth by the Inhibitor K1-5 Generated by Plasmin-Mediated Proteolysis by Cao, Renhai, Wu, Hua-Lin, Veitonmäki, Niina, Linden, Philip, Farnebo, Jacob, Shi, Guey-Yueh, Cao, Yihai

“…Proteolytic enzymes are involved in generation of a number of endogenous angiogenesis inhibitors. Previously, we reported that angiostatin, a potent…”
Get full text

The Epitope Targeted by Apoptosis-Inducing ICAM-1 Antibody B11 Is Highly Expressed in Multiple Myeloma by Hansson, Markus, Veitonmäki, Niina, Lindblom, Anders, Frendéus, Björn

“…Abstract 4897 Complex adhesive and non-cognate interactions participate in multiple myeloma disease progression, resistance to apoptosis, and development of…”
Get full text

First‐in‐human study with intratumoral administration of a CD40 agonistic antibody, ADC‐1013, in advanced solid malignancies by Irenaeus, Sandra M. M., Nielsen, Dorte, Ellmark, Peter, Yachnin, Jeffrey, Deronic, Adnan, Nilsson, Anneli, Norlén, Per, Veitonmäki, Niina, Wennersten, Camilla S., Ullenhag, Gustav J.

“…Agonistic CD40 antibodies activate dendritic cells and can expand and activate tumor‐specific T cells. Our purpose was to assess the CD40 agonistic antibody…”
Get full text

The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunity by Mangsbo, Sara M, Broos, Sissela, Fletcher, Erika, Veitonmäki, Niina, Furebring, Christina, Dahlén, Eva, Norlén, Per, Lindstedt, Malin, Tötterman, Thomas H, Ellmark, Peter

“…Local administration of immune-activating antibodies may increase the efficacy and reduce the immune-related adverse events associated with systemic…”
Get full text

Differential roles of p80- and p130-angiomotin in the switch between migration and stabilization of endothelial cells by Ernkvist, Mira, Birot, Olivier, Sinha, Indranil, Veitonmaki, Niina, Nyström, Staffan, Aase, Karin, Holmgren, Lars

“…We have previously shown that angiomotin (Amot) plays an important role in growth factor-induced migration of endothelial cells in vitro. Genetic knock-down of…”
Get full text

Endothelial cell surface ATP synthase-triggered caspase-apoptotic pathway is essential for K1-5-induced antiangiogenesis by VEITONMÄKI, Niina, RENHAI CAO, WU, Lin-Hua, MOSER, Tammy L, BO LI, PIZZO, Salvatore V, ZHIVOTOVSKY, Boris, YIHAI CAO

“…We have recently reported the identification of kringle 1-5 (K1-5) of plasminogen as a potent and specific inhibitor of angiogenesis and tumor growth. Here, we…”
Get full text

Abstract 3251: Fibroblast activation protein (FAP)-selective delivery of CD40 agonistic DARPin®molecule for tumor-localized immune activation by Rigamonti, Nicolo, Schlegel, Anja, Barsin, Sophie, Schwestermann, Jonas, Mangold, Susanne, Kaufmann, Yvonne, Zitt, Christof, Veitonmäki, Niina, Levitsky, Victor, Metz, Clara

“…Abstract CD40 is a co-stimulatory molecule belonging to the tumor necrosis factor receptor superfamily which can activate both innate and adaptive immune…”
Get full text

The Bispecific Tumor Antigen-Conditional 4-1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies by Nelson, Michelle H, Fritzell, Sara, Miller, Robert, Werchau, Doreen, Van Citters, Danielle, Nilsson, Anneli, Misher, Lynda, Ljung, Lill, Bader, Robert, Deronic, Adnan, Chunyk, Allison G, Schultz, Lena, Varas, Laura A, Rose, Nadia, Håkansson, Maria, Gross, Jane, Furebring, Christina, Pavlik, Peter, Sundstedt, Anette, Veitonmäki, Niina, Ramos, Hilario J, Säll, Anna, Dahlman, Anna, Bienvenue, David, von Schantz, Laura, McMahan, Catherine J, Askmyr, Maria, Hernandez-Hoyos, Gabriela, Ellmark, Peter

“…4-1BB (CD137) is an activation-induced costimulatory receptor that regulates immune responses of activated CD8 T and natural killer cells, by enhancing…”
Get full text

Abstract 1073: A tumor-targeted CD40 agonistic DARPin® molecule leading to antitumor activity with limited systemic toxicity by Rigamonti, Nicolo, Jetzer, Sarah, Van der Velden, Niels, Abdelmotaleb, Omar, Barsin, Sophie, Schwestermann, Jonas, Mangold, Susanne, Kaufmann, Yvonne, Bessey, Ralph, Valeri, Andrea, Poulet, Heidi, Zitt, Christof, Trail, Pamela A., Levitsky, Victor, Veitonmäki, Niina, Metz, Clara

“…Abstract CD40 is a member of the tumor necrosis factor receptor (TNFR) superfamily which can activate both innate and adaptive tumor immunity, making it an…”
Get full text

Abstract 2273: Selection of first-in-human clinical dose range for the tumor-targeted 4-1BB agonist MP0310 (AMG 506) using a pharmacokinetic/pharmacodynamics modeling approach by Link, Alexander, Juglair, Laurent, Poulet, Heïdi, Lemaillet, Guy, Reichen, Christian, Schildknecht, Patricia, Tosevski, Ivana, Robinson, Joanna, Veitonmäki, Niina, Herbst, Jörg, Dawson, Keith, Zitt, Christof, de Almeida, Camila, de Greef, Rik, Levitsky, Victor, Stumpp, Michael T., Ji, Hong, Baur, Elmar Vom

“…Abstract Following the clinical success of checkpoint inhibitors, cancer immunotherapy is rapidly expanding into combination treatments to enhance response…”
Get full text

Therapeutic antibodies targeting angiomotin inhibit angiogenesis in vivo by Levchenko, Tetyana, Veitonmäki, Niina, Lundkvist, Andrea, Gerhardt, Holger, Ming, Yue, Berggren, Kristina, Kvanta, Anders, Carlsson, Roland, Holmgren, Lars

“…We have previously shown that angiomotin (Amot) mediates angiostatin inhibition of endothelial migration and tube formation in vitro. A crucial role of…”
Get full text

Abstract 3623: The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation by Veitonmäki, Niina, Thagesson, Mia, Werchau, Doreen, Hägerbrand, Karin, Smedenfors, Kristine, Månsson-Kvarnhammar, Anne, Rosén, Anna, Johansson, Maria, Furebring, Christina, Norlén, Per, Ellmark, Peter

“…Abstract ATOR-1015 is a CTLA-4 x OX40 bispecific immune activating antibody developed for tumor-directed immunotherapy. ATOR-1015 binds both targets…”
Get full text

A Multispecific Anti-CD40 DARPin Construct Induces Tumor-Selective CD40 Activation and Tumor Regression by Rigamonti, Nicolò, Veitonmäki, Niina, Domke, Clara, Barsin, Sophie, Jetzer, Sarah, Abdelmotaleb, Omar, Bessey, Ralph, Lekishvili, Tamara, Malvezzi, Francesca, Gachechiladze, Mariam, Behe, Martin, Levitsky, Victor, Trail, Pamela A

“…The CD40 receptor is an attractive target for cancer immunotherapy. Although a modest pharmacodynamic effect is seen in patients following administration of…”
Get more information